Pro: Patient and allograft survival remain the best metric to gauge successful liver transplantation
Vijaya L. Rao, Adam E. Mikolajczyk, Geraldine C. Diaz, John F. Renz – 6 April 2018
The link between hepatitis C virus and diabetes mellitus: Improvement in insulin resistance after eradication of hepatitis C virus
Justine Hum, Janice H. Jou – 6 April 2018
A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma
Colin M. Court, Shuang Hou, Paul Winograd, Nicholas H. Segel, Qingyu Wilda Li, Yazhen Zhu, Saeed Sadeghi, Richard S. Finn, Ekambaram Ganapathy, Min Song, Samuel W. French, Bita V. Naini, Shonan Sho, Fady M. Kaldas, Ronald W. Busuttil, James S. Tomlinson, Hsian‐Rong Tseng, Vatche G. Agopian – 6 April 2018 – Current clinicopathologic staging systems and serum biomarkers poorly discriminate tumor biology in hepatocellular carcinoma (HCC), with high recurrence rates following curative‐intent surgical resection and liver transplantation (LT).
Disruption of Renal Arginine Metabolism Promotes Kidney Injury in Hepatorenal Syndrome in Mice
Zoltan V. Varga, Katalin Erdelyi, Janos Paloczi, Resat Cinar, Zsuzsanna K. Zsengeller, Tony Jourdan, Csaba Matyas, Balazs Tamas Nemeth, Adrien Guillot, Xiaogang Xiang, Adam Mehal, György Haskó, Isaac E. Stillman, Seymour Rosen, Bin Gao, George Kunos, Pal Pacher – 6 April 2018 – Tubular dysfunction is an important feature of renal injury in hepatorenal syndrome (HRS) in patients with end‐stage liver disease. The pathogenesis of kidney injury in HRS is elusive, and there are no clinically relevant rodent models of HRS.
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero, Laura M. Kulik, Claude B. Sirlin, Andrew X. Zhu, Richard S. Finn, Michael M. Abecassis, Lewis R. Roberts, Julie K. Heimbach – 6 April 2018
Hepatitis C: Who should treat hepatitis C virus? The role of the primary care provider
Tram T. Tran – 6 April 2018
Con: Patient and graft survival outcome at 1 and 3 years posttransplant do not reflect the value of successful liver transplantation
Lauren A. George, Zurabi Lominadze, Eric R. Kallwitz – 6 April 2018
Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
Jacob George, Eduard Burnevich, I‐Shyan Sheen, Jeong Heo, Nguyen Van Kinh, Tawesak Tanwandee, Pin‐Nan Cheng, Do Young Kim, Won Young Tak, Svetlana Kizhlo, Konstantin Zhdanov, Vasily Isakov, Liwen Liang, Pauline Lindore, Joy Ginanni, Bach‐Yen Nguyen, Janice Wahl, Eliav Barr, Michael Robertson, Paul Ingravallo, Rohit Talwani, on behalf of the C‐CORAL Study Investigators – 4 April 2018 – The prevalence of hepatitis C virus (HCV) infection in Asian countries is high.
Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
Jacob George, Eduard Burnevich, I‐Shyan Sheen, Jeong Heo, Nguyen Van Kinh, Tawesak Tanwandee, Pin‐Nan Cheng, Do Young Kim, Won Young Tak, Svetlana Kizhlo, Konstantin Zhdanov, Vasily Isakov, Liwen Liang, Pauline Lindore, Joy Ginanni, Bach‐Yen Nguyen, Janice Wahl, Eliav Barr, Michael Robertson, Paul Ingravallo, Rohit Talwani, on behalf of the C‐CORAL Study Investigators – 4 April 2018 – The prevalence of hepatitis C virus (HCV) infection in Asian countries is high.
Issue Information
2 April 2018